EU medicines agency recommends approval of Novartis leukaemia drug Rydapt

ZURICH (Reuters) - A European Medicines Agency (EMA) panel recommended on Friday approval of a new Novartis drug to be used against a tough-to-cure form of blood cancer as the Swiss drugmaker makes headway on refreshing its oncology portfolio.